\-\ Texto\\:\\ \ \(0\)\
\-\ ast\\:\\ 52\\ \\(h\\)\\ u\\/l\ \(0\)\
\-\ alt\\:\\ \\ 49\\ \\ \\(30\\-65\\)\\ u\\/l\ \(0\)\
\-\ aphos\\:\\ 236\\ \\(h\\)\\ u\\/l\ \(0\)\
\-\ tbili\\:\\ 0\\.7\\ mg\\/dl\ \(0\)\
\-\ dbili\\:\\ 0\\.1\\ mg\\/dl\ \(0\)\
\-\ contrast\\ enhanced\\ images\\ through\\ the\\ liver\\,\\ obtained\\ during\\ the\\ hepatic\\ arterial\\ phase\\ and\\ viewed\\ with\\ liver\\ windows\\,\\ shows\\ multiple\\ nodular\\ hypodensities\\ throughout\\ the\\ liver\\ parenchyma\\,\\ with\\ surrounding\\ peripheral\\ rim\\ enhancement\\ and\\ associated\\ wedge\\-shaped\\ high\\-attenuation\\ areas\\.\ \(0\)\
\-\ contrast\\ enhanced\\ image\\ through\\ the\\ pancreas\\ shows\\ a\\ hypodense\\ mass\\ in\\ the\\ body\\.\\ note\\ the\\ attenuation\\ difference\\ between\\ the\\ tumor\\ and\\ the\\ avidly\\ enhancing\\ normal\\ pancreas\\.\ \(0\)\
\-\ metastatic\\ pancreatic\\ adenocarcinoma\ \(0\)\
\-\ differential\\ diagnosis\\ for\\ transient\\ hepatic\\ attenuation\\ difference\\ \\(thad\\)\\:\ \(0\)\
\-\ hepatocellular\\ carcinoma\\ is\\ the\\ most\\ common\\ primary\\ hepatic\\ tumor\\ associated\\ with\\ thad\\.\\ \\ in\\ regards\\ to\\ cholangiocarcinoma\\,\\ thad\\ is\\ an\\ important\\ indirect\\ sign\\ of\\ vascular\\ invasion\\.\\ \\ metastatic\\ hypervascular\\ lesions\\ from\\ islet\\ cell\\ tumors\\,\\ carcinoids\\,\\ renal\\ cell\\ carcinoma\\,\\ and\\ breast\\ carcinoma\\ may\\ also\\ have\\ this\\ imaging\\ appearance\\.\\ \\ hemangiomas\\,\\ focal\\ nodular\\ hyperplasia\\,\\ pyogenic\\ abscess\\,\\ and\\ focal\\ eosinophilic\\ necrosis\\ are\\ additional\\ differential\\ considerations\\.\\ \\ finally\\,\\ hepatic\\ hemodynamic\\ alterations\\ caused\\ by\\ liver\\ cirrhosis\\,\\ portal\\ or\\ hepatic\\ vein\\ thrombosis\\,\\ and\\ arterioportal\\ shunts\\ may\\ result\\ in\\ thad\\.\ \(0\)\
\-\ 52\\ yo\\ male\\ with\\ ruq\\ pain\\ and\\ abnormal\\ liver\\ associated\\ enzymes\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ thad\\:\\ 0\\.16325034118456477\ \(0\)\
\-\ hepatic\\:\\ 0\\.08260403592143546\ \(0\)\
\-\ u\\/l\\:\\ 0\\.07228611821280935\ \(0\)\
\-\ liver\\:\\ 0\\.06819957201001675\ \(0\)\
\-\ difference\\:\\ 0\\.05259281674108656\ \(0\)\
\-\ mg\\/dl\\:\\ 0\\.04452023369198173\ \(0\)\
\-\ 52\\:\\ 0\\.04215591247152947\ \(0\)\
\-\ h\\:\\ 0\\.04164842880027952\ \(0\)\
\-\ 30\\-65\\:\\ 0\\.04081258529614119\ \(0\)\
\-\ aphos\\:\\ 0\\.04081258529614119\ \(0\)\
\-\ pancreas\\:\\ 0\\.04048951080996464\ \(0\)\
\-\ high\\-attenuation\\:\\ 0\\.037603570571326635\ \(0\)\
\-\ arterioportal\\:\\ 0\\.037603570571326635\ \(0\)\
\-\ 236\\:\\ 0\\.03439455584651207\ \(0\)\
\-\ carcinoids\\:\\ 0\\.03439455584651207\ \(0\)\
\-\ enhanced\\:\\ 0\\.03385614004399971\ \(0\)\
\-\ carcinoma\\:\\ 0\\.033637884305775925\ \(0\)\
\-\ dbili\\:\\ 0\\.033361483849687026\ \(0\)\
\-\ nodular\\:\\ 0\\.03318897969548066\ \(0\)\
\-\ alterations\\:\\ 0\\.03251740256823353\ \(0\)\
\-\ attenuation\\:\\ 0\\.03181130620764851\ \(0\)\
\-\ \\:\\:\\ 0\\.03139652266640736\ \(0\)\
\-\ hypodensities\\:\\ 0\\.029711218292445035\ \(0\)\
\-\ regards\\:\\ 0\\.029711218292445035\ \(0\)\
\-\ indirect\\:\\ 0\\.02930838784341897\ \(0\)\
\-\ 0\\.1\\:\\ 0\\.028937819752337782\ \(0\)\
\-\ viewed\\:\\ 0\\.028937819752337782\ \(0\)\
\-\ islet\\:\\ 0\\.028594727288663146\ \(0\)\
\-\ shunts\\:\\ 0\\.028594727288663146\ \(0\)\
\-\ hemodynamic\\:\\ 0\\.028275315846593922\ \(0\)\
\-\ associated\\:\\ 0\\.028006424470940303\ \(0\)\
\-\ wedge\\-shaped\\:\\ 0\\.027180923355555824\ \(0\)\
\-\ avidly\\:\\ 0\\.026943454400057902\ \(0\)\
\-\ tbili\\:\\ 0\\.026717574010384604\ \(0\)\
\-\ 0\\.7\\:\\ 0\\.026717574010384604\ \(0\)\
\-\ pyogenic\\:\\ 0\\.02572880502752322\ \(0\)\
\-\ enzymes\\:\\ 0\\.02572880502752322\ \(0\)\
\-\ differential\\:\\ 0\\.025119998419934533\ \(0\)\
\-\ cholangiocarcinoma\\:\\ 0\\.02491449638648774\ \(0\)\
\-\ hemangiomas\\:\\ 0\\.024625050289351934\ \(0\)\
\-\ windows\\:\\ 0\\.024095372737603118\ \(0\)\
\-\ finally\\:\\ 0\\.02397190863074126\ \(0\)\
\-\ hypervascular\\:\\ 0\\.023399621797559885\ \(0\)\
\-\ cirrhosis\\:\\ 0\\.02329318884281591\ \(0\)\
\-\ hepatocellular\\:\\ 0\\.02279489873081422\ \(0\)\
\-\ considerations\\:\\ 0\\.02279489873081422\ \(0\)\
\-\ focal\\:\\ 0\\.0225971630012815\ \(0\)\
\-\ through\\:\\ 0\\.022471824244637673\ \(0\)\
\-\ ruq\\:\\ 0\\.022260116845990864\ \(0\)\
\-\ 49\\:\\ 0\\.02193509712991101\ \(0\)\
\-\ shows\\:\\ 0\\.0217534601826748\ \(0\)\
\-\ ast\\:\\ 0\\.021486718305883612\ \(0\)\
\-\ alt\\:\\ 0\\.021486718305883612\ \(0\)\
\-\ transient\\:\\ 0\\.02141603556453737\ \(0\)\
\-\ cell\\:\\ 0\\.021372599181310056\ \(0\)\
\-\ eosinophilic\\:\\ 0\\.021210240367450176\ \(0\)\
\-\ hypodense\\:\\ 0\\.021077956235764736\ \(0\)\
\-\ portal\\:\\ 0\\.02082421440013976\ \(0\)\
\-\ metastatic\\:\\ 0\\.019917679663111944\ \(0\)\
\-\ hyperplasia\\:\\ 0\\.01949235295360373\ \(0\)\
\-\ pancreatic\\:\\ 0\\.019355506646929917\ \(0\)\
\-\ invasion\\:\\ 0\\.019051102121176302\ \(0\)\
\-\ phase\\:\\ 0\\.018609851288748872\ \(0\)\
\-\ tumor\\:\\ 0\\.01844659538528529\ \(0\)\
\-\ important\\:\\ 0\\.01777215130345335\ \(0\)\
\-\ contrast\\:\\ 0\\.017710885988962085\ \(0\)\
\-\ may\\:\\ 0\\.017354892304612256\ \(0\)\
\-\ arterial\\:\\ 0\\.01731641022561422\ \(0\)\
\-\ adenocarcinoma\\:\\ 0\\.01709052983594092\ \(0\)\
\-\ thrombosis\\:\\ 0\\.016981592347930764\ \(0\)\
\-\ parenchyma\\:\\ 0\\.016848929126817912\ \(0\)\
\-\ rim\\:\\ 0\\.016745469410651262\ \(0\)\
\-\ caused\\:\\ 0\\.01659448984774033\ \(0\)\
\-\ \\,\\:\\ 0\\.016292735424651553\ \(0\)\
\-\ additional\\:\\ 0\\.01586317913958332\ \(0\)\
\-\ necrosis\\:\\ 0\\.015616207006688447\ \(0\)\
\-\ note\\:\\ 0\\.015268821886582363\ \(0\)\
\-\ result\\:\\ 0\\.015176778504388711\ \(0\)\
\-\ tumors\\:\\ 0\\.014859797952178245\ \(0\)\
\-\ throughout\\:\\ 0\\.014809015399536697\ \(0\)\
\-\ breast\\:\\ 0\\.014595175665882185\ \(0\)\
\-\ peripheral\\:\\ 0\\.014314506120435727\ \(0\)\
\-\ vein\\:\\ 0\\.014314506120435727\ \(0\)\
\-\ obtained\\:\\ 0\\.014064194910851119\ \(0\)\
\-\ sign\\:\\ 0\\.013705770841500327\ \(0\)\
\-\ \\(\\:\\ 0\\.013377069004515935\ \(0\)\
\-\ areas\\:\\ 0\\.01331179245947253\ \(0\)\
\-\ \\)\\:\\ 0\\.013213660965061205\ \(0\)\
\-\ surrounding\\:\\ 0\\.013005394742429469\ \(0\)\
\-\ vascular\\:\\ 0\\.012971311425572668\ \(0\)\
\-\ body\\:\\ 0\\.012848443114301316\ \(0\)\
\-\ between\\:\\ 0\\.01253933118622335\ \(0\)\
\-\ abscess\\:\\ 0\\.012508501130251237\ \(0\)\
\-\ enhancing\\:\\ 0\\.012407192281873885\ \(0\)\
\-\ image\\:\\ 0\\.01235735725137778\ \(0\)\
\-\ during\\:\\ 0\\.012106524305202815\ \(0\)\
\-\ yo\\:\\ 0\\.011904405200475749\ \(0\)\
\-\ renal\\:\\ 0\\.01188646087712069\ \(0\)\
\-\ primary\\:\\ 0\\.011719371587480076\ \(0\)\
\-\ appearance\\:\\ 0\\.011314382299697414\ \(0\)\
\-\ abnormal\\:\\ 0\\.011282834445902367\ \(0\)\
\-\ enhancement\\:\\ 0\\.010604114657977018\ \(0\)\
\-\ lesions\\:\\ 0\\.010590557899740498\ \(0\)\
\-\ common\\:\\ 0\\.010353088944242578\ \(0\)\
\-\ imaging\\:\\ 0\\.009268860298405568\ \(0\)\
\-\ most\\:\\ 0\\.00913349602651887\ \(0\)\
\-\ diagnosis\\:\\ 0\\.009084348753613055\ \(0\)\
\-\ have\\:\\ 0\\.008566842955393943\ \(0\)\
\-\ multiple\\:\\ 0\\.00833243520129291\ \(0\)\
\-\ also\\:\\ 0\\.00779916478550996\ \(0\)\
\-\ images\\:\\ 0\\.007589184684950713\ \(0\)\
\-\ male\\:\\ 0\\.007153729342071635\ \(0\)\
\-\ by\\:\\ 0\\.006587365292800346\ \(0\)\
\-\ normal\\:\\ 0\\.006201909512032875\ \(0\)\
\-\ from\\:\\ 0\\.0058631283016398715\ \(0\)\
\-\ in\\:\\ 0\\.00585273930750354\ \(0\)\
\-\ and\\:\\ 0\\.005833625185766338\ \(0\)\
\-\ the\\:\\ 0\\.005760386862651075\ \(0\)\
\-\ mass\\:\\ 0\\.00550213429142391\ \(0\)\
\-\ an\\:\\ 0\\.00547067066798486\ \(0\)\
\-\ are\\:\\ 0\\.005392934595044452\ \(0\)\
\-\ is\\:\\ 0\\.0052063960961548665\ \(0\)\
\-\ pain\\:\\ 0\\.004831519294123772\ \(0\)\
\-\ or\\:\\ 0\\.0046366793933504975\ \(0\)\
\-\ this\\:\\ 0\\.004449709320898764\ \(0\)\
\-\ for\\:\\ 0\\.003375500688160718\ \(0\)\
\-\ with\\:\\ 0\\.0021667440016646246\ \(0\)\
\-\ to\\:\\ 0\\.001977167168717529\ \(0\)\
\-\ a\\:\\ 0\\.0018361101936046353\ \(0\)\
\-\ \\.\\:\\ 0\\.0014791473373894281\ \(0\)\
\-\ of\\:\\ 0\\.0005393694481388353\ \(0\)\
